These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 12016246)
1. Why were the benefits of tPA exaggerated? Trotter G West J Med; 2002 May; 176(3):194-7. PubMed ID: 12016246 [No Abstract] [Full Text] [Related]
2. Tissue plasminogen activator (tPA) for acute ischaemic stroke: why so much has been made of so little. Hoffman JR Med J Aust; 2003 Oct; 179(7):333-4. PubMed ID: 14503891 [No Abstract] [Full Text] [Related]
3. Testing new ideas: is a picture worth a thousand words? Yealy DM; Callaham ML Ann Emerg Med; 2009 Sep; 54(3):337-8. PubMed ID: 19695416 [No Abstract] [Full Text] [Related]
4. Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility. Fink JN; Selim MH; Kumar S; Schlaug G Neurology; 2001 Nov; 57(9):1739-40. PubMed ID: 11706134 [No Abstract] [Full Text] [Related]
5. Alteplase for stroke. Financial information is needed to ensure objectivity. Solomon RC BMJ; 2002 Jun; 324(7353):1581; author reply 1581. PubMed ID: 12092607 [No Abstract] [Full Text] [Related]
6. Response to "A graphic reanalysis of the NINDS Trial". Dewey HM; Churilov L; Blacker D; Bladin C; Davis SM; Donnan GA; Gates P; Gerraty RP; Hand P; Levi C; Lindley RI; Markus R; Read S Ann Emerg Med; 2010 Feb; 55(2):227-9; author reply 229. PubMed ID: 20116035 [No Abstract] [Full Text] [Related]
7. Response to: "A graphic reanalysis of the NINDS Trial". Saver JL; Gornbein J; Starkman S Ann Emerg Med; 2010 Feb; 55(2):226-7; author reply 229. PubMed ID: 20116034 [No Abstract] [Full Text] [Related]
8. Be careful when extrapolating trial data to real life. Dudley N BMJ; 2003 Oct; 327(7418):812. PubMed ID: 14525900 [No Abstract] [Full Text] [Related]
9. Tissue-type plasminogen activator as a therapeutic target in stroke. Gravanis I; Tsirka SE Expert Opin Ther Targets; 2008 Feb; 12(2):159-70. PubMed ID: 18208365 [TBL] [Abstract][Full Text] [Related]
10. Emergency physician survey: recombinant tissue plasminogen activator for stroke. Mann J Ann Emerg Med; 2006 Oct; 48(4):476; author reply 477. PubMed ID: 16997689 [No Abstract] [Full Text] [Related]
14. NINDS Reanalysis Committee's reanalysis of the NINDS trial. Mann J Stroke; 2005 Feb; 36(2):230-1; author reply 230-1. PubMed ID: 15637327 [No Abstract] [Full Text] [Related]
15. Expectations for tPA is pathway to litigation. ED Manag; 2011 Feb; 23(2):18-9. PubMed ID: 21400969 [No Abstract] [Full Text] [Related]
16. Using tPA for acute stroke in a rural setting. Gross H; Hall C; Switzer JA; Adams RJ; Wang S; Hess DC; Nichols FT; Pardue C Neurology; 2007 May; 68(22):1957-8; author reply 1958. PubMed ID: 17536059 [No Abstract] [Full Text] [Related]
17. [Thrombolytic therapy with tPA for the treatment of acute stroke. The Standard Treatment with Alteplase to Reverse Stroke study]. Di Pasquale G Ital Heart J Suppl; 2000 Jul; 1(7):947-8. PubMed ID: 10935744 [No Abstract] [Full Text] [Related]
18. A hundred (and one) graphs tell only part of the story. Silbergleit R Ann Emerg Med; 2009 Sep; 54(3):342-3. PubMed ID: 19695418 [No Abstract] [Full Text] [Related]
19. A brief history of acute stroke care. Damani R Aging (Albany NY); 2018 Aug; 10(8):1797-1798. PubMed ID: 30157473 [No Abstract] [Full Text] [Related]
20. Right brain: my first tPA. Robbins MS Neurology; 2009 Jul; 73(2):e9-e10. PubMed ID: 19597130 [No Abstract] [Full Text] [Related] [Next] [New Search]